Paramjeet K Randhawa, a director at Hercules Capital, Inc., purchased 2,926 shares of the business on March 26, 2026, paying a total of $41,988 for the equity. The shares were acquired at an average price of $14.35, with execution prices ranging from $14.31 to $14.39.
The transaction was made under Randhawa's election to receive stock in lieu of cash compensation, and it lifts his direct ownership in Hercules Capital to 22,486 shares. At the time of the disclosure, Hercules Capital's common stock was trading at $14.16, a level noted as being close to its 52-week low of $13.70.
Hercules Capital provides a dividend yield of 13.53%, according to InvestingPro data. InvestingPro also is noted as providing access to over 10 additional ProTips and comprehensive Pro Research Reports for HTGC and 1,400+ other US equities.
In related corporate developments disclosed recently, Hercules Capital issued preliminary estimates for its fourth-quarter and year-end financial position, projecting net asset value per share between $12.10 and $12.16 as of December 31, 2025. That range represents an increase from the NAV per share of $12.05 reported as of September 30, 2025.
The company also amended its loan agreement with Savara Inc., arranging for up to an additional $75 million in funding that will become available contingent on FDA approval of Savara's investigational therapy, MOLBREEVI.
On the equity research front, Piper Sandler downgraded Hercules Capital's rating from Overweight to Neutral. The brokerage cited concern over the company's 35% exposure to the software sector, pointing to potential AI disruption risks as a factor behind its change in stance. Piper Sandler also trimmed its price target for Hercules Capital to $17.50 from $20.50.
Short-seller Hunterbrook published a report raising questions about how Hercules Capital values its software-related debt and the sustainability of its dividend. Hunterbrook highlighted that 35% of the firm's loan portfolio is exposed to software debt and disclosed that it holds a short position in Hercules Capital while being long a basket of comparable securities.
These combined disclosures - an insider election to receive stock, preliminary NAV improvements, a conditional lending amendment, an analyst downgrade, and a critical short report - present a layered picture of activity around Hercules Capital. The director purchase increases an insider's stake but sits alongside external concerns about portfolio mix and dividend durability.
The company's stated NAV range, the contingency on Savara funding tied to regulatory approval, and the attention from both an analyst downgrade and a short report are all facts disclosed by the company and external market participants. Observers evaluating the equity should weigh the exact figures provided above when considering position sizing or comparative valuation work.